FDA’s Real-World Evidence Demonstration Projects: an interview with Motiur Rahman, FDA

In exploring the wider application of real-world data (RWD) and real-world evidence (RWE), demonstration projects are being increasingly utilized by various stakeholders to evaluate the feasibility, reliability, and relevance of RWD sources and methodologies for generating RWE before they can potentially be widely implemented. Here Motiur Rahman (Senior Epidemiologist for Real-World Evidence Analytics, Office of Medical Policy, Center for Drug Evaluation and Research, FDA, USA) discusses how the FDA is using demonstration projects as part of its RWE program. Motiur recently spoke on this topic at the DIA Real-World Evidence Conference 2023. Please could you introduce yourself and your role...